F9302
Factor X Activated (Xa) from bovine plasma
aqueous glycerol solution
Sinonimo/i:
Factor Xa
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Numero CAS:
Numero MDL:
Codice UNSPSC:
12352204
NACRES:
NA.54
Prodotti consigliati
Forma fisica
aqueous glycerol solution
Livello qualitativo
Attività specifica
≥50 units/mg protein
N° accesso UniProt
Condizioni di spedizione
wet ice
Temperatura di conservazione
−20°C
Informazioni sul gene
cow ... F10(280787)
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Applicazioni
Fusion proteins are commonly expressed with a factor Xa cleavable Ile-Glu (or Asp)-Gly-Arg-↓-X sequence. Typically 1 mg of fusion protein can be incubated with 10 μg of factor Xa for 2.5 hours at 37 °C.
Azioni biochim/fisiol
Factor Xa catalyzes the hydrolysis of the Arg-Thr and then Arg-Ile bonds in prothrombin to yield active thrombin.
The fairly strict recognition sequence is Ile-Glu (or Asp)-Gly-Arg-↓-X.
It may sometimes cleave at other basic residues, depending on the conformation of the target protein. Factor Xa will not cleave if a proline residue follows the arginine of the recognition sequence.
pH Optimum: 7.6-8.0
Temperature Optimum: 37 °C
The fairly strict recognition sequence is Ile-Glu (or Asp)-Gly-Arg-↓-X.
It may sometimes cleave at other basic residues, depending on the conformation of the target protein. Factor Xa will not cleave if a proline residue follows the arginine of the recognition sequence.
pH Optimum: 7.6-8.0
Temperature Optimum: 37 °C
Proprietà fisiche
Factor Xa is a serine endoproteinase and a member of the S1 peptidase family. Factor Xa plays a critical role in the coagulation cascade by catalyzing the proteolytic conversion of prothrombin to active thrombin. Factor Xa′s prothrombin conversion activity is greatly enhanced in vivo when complexed with factor V, calcium ions and phospholipids on the activated platelet surface.
The zymogen form, Factor X, is activated in vivo by two different pathways. The intrinsic pathway utilizes a catalytic complex composed of factor IXa, factor VIII, phospholipids and calcium ions. The extrinsic pathway utilizes a complex of factor VII and tissue factor. The factor X zymogen is a 55 KDa glycoprotein with a light and heavy chain joined by a single disulfide.
The zymogen form, Factor X, is activated in vivo by two different pathways. The intrinsic pathway utilizes a catalytic complex composed of factor IXa, factor VIII, phospholipids and calcium ions. The extrinsic pathway utilizes a complex of factor VII and tissue factor. The factor X zymogen is a 55 KDa glycoprotein with a light and heavy chain joined by a single disulfide.
Definizione di unità
One unit of activated Factor X will liberate 1.0 μmole of p-nitroanilide from N-benzoyl-L-isoleucyl-L-glutamyl-L-glycyl-L-arginine-p-nitroaniline per minute at pH 8.3 at 37 °C.
Esclusione di responsabilità
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Substrato
N° Catalogo
Descrizione
Determinazione del prezzo
Codice della classe di stoccaggio
10 - Combustible liquids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Taki Galanis et al.
Hospital practice (1995), 41(1), 26-36 (2013-03-08)
Nonvalvular atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia occurring in patients in the United States. The primary clinical consequence of AF is an increase in the risk and severity of strokes. Treatment guidelines recommend anticoagulation therapy
Antidotes edge closer to reversing effects of new blood thinners.
Elie Dolgin
Nature medicine, 19(3), 251-251 (2013-03-08)
Alexander T Cohen et al.
The New England journal of medicine, 368(6), 513-523 (2013-02-08)
The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin
Genmin Lu et al.
Nature medicine, 19(4), 446-451 (2013-03-05)
Inhibitors of coagulation factor Xa (fXa) have emerged as a new class of antithrombotics but lack effective antidotes for patients experiencing serious bleeding. We designed and expressed a modified form of fXa as an antidote for fXa inhibitors. This recombinant
Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation.
The Medical letter on drugs and therapeutics, 55(1409), 9-10 (2013-02-06)
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.